Gulsum Emel Pamuk

Dr. Gulsum Emel Pamuk


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
GPGulsum Emel Pamuk
Gulsum Emel Pamuk
LELori A. Ehrlich
Lori A. Ehrlich
Myeloid blast-phase chronic myeloid leukemia (MBP-CML) is a rare disease with a dismal prognosis. It is twice as common as lymphoid blast-phase CML, and its prognosis is poorer. Despite the success with tyrosine kinase inhibitors in the treatment of chronic-phase CML, the same does not hold true for MBP-CML. In addition to the Philadelphia chromosome, other chromosomal and molecular changes characterize rapid progression. Although some progress in elucidating the biology of MBP-CML has been made, there is need to discover more in order to develop more satisfactory treatment options. Currently, most common treatment options include tyrosine kinase inhibitors (TKIs) as monotherapy or in combination with acute myeloid leukemia-based intensive chemotherapy regimens. Some patients may develop resistance to TKIs via BCR-ABL1-dependent or BCR-ABL1-independent mechanisms. In this paper, we provide an overview of the biology of MBP-CML, the current treatment approaches, and mechanisms of resistance to TKIs. In order to improve treatment responses in these patients, more emphasis should be placed on understanding the biology of myeloid blastic transformation in CML and mechanisms of resistance to TKIs. Although patient numbers are small, randomized clinical trials should be considered.

1 August 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
GPGulsum Emel Pamuk
Gulsum Emel Pamuk
ECEdwin C.Y. Chow
Edwin C.Y. Chow
AIAlexei C. Ionan
Alexei C. Ionan
HCHaiyan Chen
Haiyan Chen
SLShwu-Luan Lee
Shwu-Luan Lee
MTMarc R. Theoret
Marc R. Theoret
On October 29, 2021, FDA granted accelerated approval to asciminib (SCEMBLIX; Novartis), a tyrosine kinase inhibitor (TKI), for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more TKIs, and granted traditional approval to asciminib for adult patients with Ph+ CML in CP with the T315I mutation. The first indication was approved based on major molecular response (MMR) at 24 weeks in the ASCEMBL study, a randomized trial comparing asciminib with bosutinib in patients who had failed two or more TKIs. This indication was ultimately granted traditional approval on October 12, 2022, based on safety data and MMR rate at 96 weeks of 38% [95% confidence interval (CI), 30–46] in the asciminib arm versus 16% (95% CI, 8–26) in the bosutinib arm (P value: 0.001). The second indication was approved based on MMR rate by 96 weeks of 49% (95% CI, 34–64) in the single-arm CABL001X2101 study. The most common (≥20%) adverse reactions included upper respiratory tract infections, musculoskeletal pain, headache, fatigue, nausea, rash, and diarrhea. The most common (≥20%) laboratory abnormalities were thrombocytopenia, neutropenia, anemia, lymphopenia, hypertriglyceridemia, hyperuricemia, and increases in creatine kinase, alanine aminotransferase, aspartate aminotransferase, lipase, and amylase. This manuscript describes the basis for approval of these indications.

2 December 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
EDElizabeth S. Duke
Elizabeth S. Duke
MFMichael J. Fusco
Michael J. Fusco
PDPatrick DeMoss
Patrick DeMoss
ADAsma Dilawari
Asma Dilawari
GPGulsum Emel Pamuk
Gulsum Emel Pamuk
RPRichard Pazdur
Richard Pazdur
Summary: In 2022, cancer drug development continued to progress rapidly despite the lingering COVID-19 pandemic. Highlights of U.S. drug approvals for oncology indications this year include ongoing development in rare diseases and molecular subgroups, improved dosage optimization, and updated data for drugs granted accelerated approval, with confirmatory studies demonstrating verification of clinical benefit in some instances, as well as indication withdrawal when clinical benefit was not verified.

22 December 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KSKendra L. Sweet
Kendra L. Sweet
JCJorge Cortes
Jorge Cortes
JAJane FELICITY Apperley
Jane FELICITY Apperley
MMMel Mann
Mel Mann
MMMichael J. Mauro
Michael J. Mauro
KNKelly J. Norsworthy
Kelly J. Norsworthy
The FDA has an accelerated approval program for drugs that have been identified as promising treatments for serious conditions when the available data suggest that the benefits outweigh the foreseeable risks. All of the currently available treatment options for chronic myeloid leukemia (CML) initially went through the accelerated approval program. Here, a group of academic CML experts, patient panelists, and members from the FDA convened to discuss the utility of the accelerated approval program as it pertains to CML, and the utility of this program in future drug development in this disease. The results of that discussion are summarized here.

12 December 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JDJoshua M. Donaldson
Joshua M. Donaldson
MSMarjilla Seddiq
Marjilla Seddiq
MFMichael J. Fusco
Michael J. Fusco
SSShyamli Singla
Shyamli Singla
GPGulsum Emel Pamuk
Gulsum Emel Pamuk
RPRichard Pazdur
Richard Pazdur
Summary: Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.

17 June 2026
Verified
Other
Open access
GPGulsum Emel Pamuk
Gulsum Emel Pamuk
ECEdwin C.Y. Chow
Edwin C.Y. Chow
AIAlexei C. Ionan
Alexei C. Ionan
HCHaiyan Chen
Haiyan Chen
SLShwu-Luan Lee
Shwu-Luan Lee
MTMarc R. Theoret
Marc R. Theoret
Select laboratory abnormalities (≥ 10%) that worsened from baseline in patients with Ph + CML in CP with the T315I mutation in X2101 trial